Top HHS research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology) contractors
In the 12 months ending Oct 5, 2026, the Department of Health and Human Services obligated $1.8B in net prime contract dollars under NAICS 541715, up 25.6% from $1.4B in the preceding 12 months. 231 prime contractors received positive obligations, and 31 of them accounted for 80% of that spend.
Prime contracts funded by the Department of Health and Human Services. Latest 12 months: Oct 6, 2025 to Oct 5, 2026. Source: USAspending.gov.
Obligations by fiscal year
Net prime contract obligations by federal fiscal year (October to September).
Top HHS contractors for NAICS 541715
Ranked by positive obligations in the latest 12 months. Share is of all positive obligations in this market.
| # | Contractor | Latest 12 mo | Prior 12 mo | Share | Rank change |
|---|---|---|---|---|---|
| 1 | Leidos Biomedical Research Inc | $776.3M | $572.1M | 42.3% | — |
| 2 | The MITRE Corporation | $169.3M | $123.7M | 9.2% | — |
| 3 | Westat, Inc. | $86.7M | $70.9M | 4.7% | — |
| 4 | Technical Resources International, Inc. | $46.9M | $46.1M | 2.5% | — |
| 5 | Duke University | $43.6M | $26.5M | 2.4% | — |
| 6 | American Type Culture Collection | $24.9M | $23.1M | 1.4% | ▲ 1 |
| 7 | Battelle Memorial Institute | $24.3M | $18.5M | 1.3% | ▲ 3 |
| 8 | Scynexis Inc | $18.5M | $0 | 1.0% | New |
| 9 | The Emmes Company, LLC | $17.6M | $17.9M | 1.0% | ▲ 3 |
| 10 | SRI International | $17.0M | $19.6M | 0.9% | ▼ 2 |
| 11 | University of Pittsburgh - of the Commonwealth System of Higher Education | $16.5M | $0 | 0.9% | New |
| 12 | Fred Hutchinson Cancer Center | $15.1M | $13.6M | 0.8% | ▲ 2 |
| 13 | Flosonics Medical LLC | $15.0M | $0 | 0.8% | New |
| 14 | Icahn School of Medicine at Mount Sinai | $14.5M | $25.3M | 0.8% | ▼ 8 |
| 15 | Revagenix Inc | $14.2M | $671K | 0.8% | ▲ 116 |
What changed in the last 12 months
Contractors with the largest change in reported obligations versus the preceding 12 months.
Largest gains
- Leidos Biomedical Research Inc$572.1M → $776.3M (+$204.1M) · now #1
- The MITRE Corporation$123.7M → $169.3M (+$45.6M) · now #2
- Scynexis Inc$0 → $18.5M (+$18.5M) · now #8
Largest declines
- Icahn School of Medicine at Mount Sinai$25.3M → $14.5M (−$10.8M) · now #14
- Rivanna Medical, Inc.$9.9M → $0 (−$9.9M) · no latest-period obligations
- University of Georgia Research Foundation, Inc.$11.8M → $4.9M (−$6.9M) · now #48
New to this market
53 contractors received their first obligations in this market (since FY2022) during the latest 12 months. The largest:
| Contractor | First obligation | Latest 12 mo |
|---|---|---|
| Scynexis Inc | Sep 25, 2026 | $18.5M |
| Flosonics Medical LLC | Jun 5, 2026 | $15.0M |
| The University of Texas Health Science Center at SAN Antonio | Apr 22, 2026 | $9.4M |
| Chippewa Government Solutions, LLC | Jun 26, 2026 | $7.0M |
| The Medical Device Innovation Consortium | Sep 21, 2026 | $6.0M |
| EEC-Lukos JV, LLC | Mar 20, 2026 | $5.8M |
| Sciome LLC | Aug 25, 2026 | $5.5M |
| SNC Therapeutics, Inc. | Sep 24, 2026 | $3.5M |
Where the money comes from
Funding sub-agencies within the Department of Health and Human Services, latest 12 months. The funding organization can differ from the office that runs the requirement.
| Funding sub-agency | Latest 12 mo | Prior 12 mo | Change |
|---|---|---|---|
| National Institutes of Health | $1.5B | $1.3B | Up $261.8M (20.7%) |
| Centers for Medicare and Medicaid Services | $123.2M | $99.8M | Up $23.4M (23.4%) |
| Office of Assistant Secretary for Preparedness and Response | $83.0M | $20.6M | Up $62.4M (302.5%) |
| Food and Drug Administration | $40.7M | $12.2M | Up $28.4M (232.2%) |
| Centers for Disease Control and Prevention | $27.3M | $33.4M | Down $6.1M (18.1%) |
| Office of the Assistant Secretary for Financial Resources | $12.2M | $0 | New |
Potential recompetes
Large awards in this market whose current period of performance ends in the next 18 months. Treat these as research leads: options, extensions, and follow-on vehicles often change the timing.
| Award | Incumbent | Obligated | Current end |
|---|---|---|---|
| 75A50223C00024 | Safesource Direct LLC INDUSTRIAL BASE EXPANSION OF NBR | $144.8M | Dec 15, 2026 |
| 75N93024C00004 | Technical Resources International, Inc. CLINICAL RESEARCH OPERATIONS AND MANAGEMENT SUPPORT (CROMS) | $72.7M | Mar 31, 2027 |
| 75N91021C00013 | Technical Resources International, Inc. PURPOSE: TO PROVIDE CLINICAL TRIALS SPONSOR AND REGULATORY MANAGEMENT SUPPORT SERVICES TO THE NCI, THE CENTER FOR CANCER RESEARCH (CCR), AND CCR INVESTIGATORS. | $58.5M | Jun 30, 2027 |
| 75N93019C00051 | Icahn School of Medicine at Mount Sinai THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,… | $60.4M | Jul 9, 2027 |
| 75N91022F00001 | Westat, Inc. TASK ORDER 1A: PROJECT KICK-OFF MEETING AND TASK ORDER 2A: CTSU CORE SUPPORT SERVICES & THE CTSU ENTERPRISE OF SYSTEMS; CANCER TRIALS SUPPORT UNIT (CTSU) IDIQ | $97.2M | Jul 31, 2027 |
| 75N91025F00016 | Leidos Biomedical Research Inc NCI OPERATIONAL TASK ORDER, FY26-FY27 | $826.0M | Aug 30, 2027 |
| 75N91025F00014 | Leidos Biomedical Research Inc NIAID VRC FY26-27 OPERATIONAL TASK ORDER | $87.8M | Aug 30, 2027 |
| 75N96024C00005 | Battelle Memorial Institute TO SUPPORT AND ASSIST THE NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES BY CONDUCTING ONGOING AND RECURRING EVALUATIONS OF THE TOXIC AND CARCINOGENIC POTENTIAL OF CHEMICAL,… | $56.7M | Sep 15, 2027 |
| 75N91021F00013 | Leidos Biomedical Research Inc ENABLING NCI CLINICAL & RESEARCH DATA SHARING | $83.6M | Feb 28, 2028 |
| 75N93021C00014 | Icahn School of Medicine at Mount Sinai MSSM CEIRR - THIS CONTRACT WILL SUPPORT THE NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE. | $59.6M | Mar 24, 2028 |
Common questions
Who are the top HHS contractors for NAICS 541715?
In the latest 12 months, Leidos Biomedical Research Inc ($776.3M), The MITRE Corporation ($169.3M), Westat, Inc. ($86.7M) received the most HHS obligations for research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology).
How concentrated is this market?
The eight largest primes held 64.9% of positive obligations, and Leidos Biomedical Research Inc alone held 42.3%. 53 contractors won their first obligations in this market during the latest 12 months.
Are any large HHS NAICS 541715 contracts ending soon?
10 of the largest awards in this market reach their current end date in the next 18 months. The first is 75A50223C00024 (Safesource Direct LLC, $144.8M obligated), ending Dec 15, 2026. An end date is a research lead, not a confirmed recompete: options and extensions often move it.
Related markets
NAICS 541715 across all agencies
DoD · NAICS 541715
$30.0BNASA · NAICS 541715
$5.8BDOE · NAICS 541715
$3.6BDHS · NAICS 541715
$321.6MCommerce · NAICS 541715
$162.2MDOT · NAICS 541715
$137.1MEPA · NAICS 541715
$48.9MUSDA · NAICS 541715
$47.8MFigures are net obligations on prime contracts (award types A–D) from USAspending.gov, grouped by funding agency and the NAICS code on each award. Net obligations include deobligations and corrections, so they can differ from positive-obligation totals. See methodology.
Ready to connect your pursuit work?
GovEagle gives BD directors, capture managers, and proposal teams one AI workspace from pipeline through proposal, with CMMC/FedRAMP Certified compliance built in.